Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 15/20 | 0.38 |
| ▸ | CPB1 | P15086 | 6/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3012492 | 0.78 | CPB2 (0.52) | CPB2CPB1 | |
| SCHEMBL27781555 | 0.76 | CPB2 (0.54) | CPB2CPB1 | |
| SCHEMBL3014228 | 0.74 | CPB2 (0.54) | CPB2CPB1 | |
| SCHEMBL3001143 | 0.73 | CPB2 (0.53) | CPB2CPB1 | |
| SCHEMBL13204160 | 0.73 | CPB2 (0.33) | CPB2CPB1 | |
| SCHEMBL14420582 | 0.73 | CPB2 (0.43) | CPB2CPB1 | |
| SCHEMBL14481389 | 0.73 | CPB2 (0.44) | CPB2CPB1 | |
| SCHEMBL2176873 | 0.71 | CYP2C9 (0.53) | CPB2CPB1 | |
| SCHEMBL2998713 | 0.70 | ALDH1A1 (0.37) | CPB2CPB1 | |
| SCHEMBL14551478 | 0.69 | CPB2 (0.39) | CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786135-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7781450-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-24 | — | — | US | disclosed |
| US-7705015-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-20090181982-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | ZHANG HAN-CHENG | 2009-07-16 | — | — | US | disclosed |
| US-20090176806-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | ZHANG HAN-CHENG | 2009-07-09 | — | — | US | disclosed |
| US-7524858-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176806-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | PRKDC, PRKACA, MAP3K20 | CPB2 2846/4885CPB1 2404/4885 |
| US-20090181982-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | PRKDC, PRKACA, MAP3K20 | CPB2 2846/4885CPB1 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.